Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Leukemia, Myeloid, Acute 12Myelodysplastic Syndromes 11Hodgkin Disease 8Lymphoma, Non-Hodgkin 7Multiple Myeloma 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Leukemia, Myelomonocytic, Chronic 5Myeloproliferative Disorders 4Lymphoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia 4Burkitt Lymphoma 4Anemia, Refractory, with Excess of Blasts 4Recurrence 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Biphenotypic, Acute 3Colorectal Neoplasms 3Blastic Plasmacytoid Dendritic Cell Neoplasm 3Stomach Neoplasms 2Sarcoma 2Primary Myelofibrosis 2Pancreatic Neoplasms 2Osteosarcoma 2Neuroblastoma 2Neoplasms, Plasma Cell 2

Interventions

fludarabine phosphate 1Specimen Handling 1Leukapheresis 1Cyclophosphamide 1Blood Component Removal 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Prolymphocytic, B-Cell × fludarabine phosphate × 30 days × Clear all
NCT05418088 2026-05-29

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Ohio State University Comprehensive Cancer Center

Phase 1 Recruiting
54 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡